Sequent Medical develops catheter-based neurovascular devices including the VIA® Microcatheter and the WEB Aneurysm Embolization System. The VIA Microcatheter has received the CE mark and was cleared for commercial use in the United States. The WEB Aneurysm Embolization System has received the CE mark but is not approved for use in the United States. The company plans to use new funding to continue introducing the WEB system, execute a planned U.S. IDE clinical study, and broaden its product portfolio. Sequent was founded in 2007 and is led by President and CEO Tom Wilder. It has operations in Aliso Viejo, California and European operations based in Bonn, Germany. Sequent Medical is a neurovascular device company based in Aliso Viejo, California, focused on developing catheter-based technologies for neurovascular specialists. Its core product is the WEB Aneurysm Embolization System, an intrasaccular device built on the company's proprietary MicroBraid technology designed to bridge the neck of ruptured or unruptured intracranial aneurysms and promote rapid peri-procedural stasis. The WEB has received the CE Mark and is available at select centers in Europe and other countries, but it is not available for use in the United States. Sequent also maintains a European operation in Bonn, Germany. The company is led by President and CEO Tom Wilder. Sequent intends to use recently raised capital to support its clinical, commercial, and technology development programs, including further development and support of the WEB. Sequent Medical develops devices to advance endovascular treatment of neurovascular disease, operating from Aliso Viejo, California. Its lead product is the WEB(TM) aneurysm embolization system, intended as a new treatment alternative for cerebral aneurysms, particularly those prone to high recurrence. The company completed a $15.6M Series B venture financing to support ongoing work. Management stated the funds will be used to continue development programs and to introduce the initial WEB product line. Tom Wilder joined as President and CEO in February 2010. The company plans to use the proceeds to advance its clinical and product introduction efforts.

Total raised

$62M

Funding rounds

3

Latest round

Series D

Latest activity

Apr 2014